Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685919 · ClinicalTrials.gov registry record · Phase 2
Peripheral Dopamine in Postural Tachycardia Syndrome
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00685919 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 32 participants.
The verdict
NCT00685919, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients with postural tachycardia syndrome (POTS). We will test the null hypothesis (Ho) that the effects of oral carbidopa administration on urinary sodium excretion will not differ between patients with POTS and healthy volunteers.
Interventions
- DRUG Placebo
- DRUG Carbidopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-05 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685919
The ClinicalTrials.gov registry entry for NCT00685919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00685919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685919 about?
NCT00685919 is a clinical study titled "Peripheral Dopamine in Postural Tachycardia Syndrome". The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients w...
What is the current status of trial NCT00685919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2008-05. Estimated completion is 2021-12.
What interventions are being tested in trial NCT00685919?
The interventions under investigation include: Placebo (DRUG), Carbidopa (DRUG).
Who is sponsoring clinical trial NCT00685919?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.